AbbVie recently announced topline Phase 3 results from the EPCORE DLBCL-1 trial, showing improved progression-free survival ...
As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results